alloferin
pacific pharmaceuticals limited (part of mylan) - alcuronium chloride 5 mg/ml - solution for injection - 10mg/2ml - active: alcuronium chloride 5 mg/ml
alloferin
pharmaco distribution (pty) ltd - alcuronium chloride - injection - alcuronium chloride solution for iv injection, 10mg/2ml
alloferine"roche"10 mg/2 ml amp.
misr - injection - 10 mg/2ml
alloferine injectable solution 10 mg/2ml
al jishi pharmacy - alcuronium chloride - injectable solution - 10
alloferin ampoules
roche products ltd - alcuronium chloride - 10mg/2 milligram
allorin allopurinol 300mg tablet
medis pharma pty ltd - allopurinol, quantity: 300 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; magnesium stearate - indications: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6- phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allorin is indicated for the management of 2, 8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allorin is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.
allorin allopurinol 100mg tablet
medis pharma pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; magnesium stearate - indications: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6- phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allorin is indicated for the management of 2, 8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allorin is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.
allorin
actavis pty ltd - allopurinol -
allorin
douglas pharmaceuticals limited - allopurinol 100mg - tablet - 100 mg - active: allopurinol 100mg excipient: lactose monohydrate magnesium stearate maize starch povidone - · allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. it is not, however, used to treat an acute attack of gout as it has no analgesic, antiinflammatory or uricosuric activity and may prolong the attack. if changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. in severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.
allorin
douglas pharmaceuticals limited - allopurinol 300mg - tablet - 300 mg - active: allopurinol 300mg excipient: lactose monohydrate magnesium stearate maize starch povidone